Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
cediranib
Description:
Cediranib is an oral small-molecule drug that inhibits vascular endothelial growth factor receptors and has been studied as an anticancer therapy.
Related topics:
PARP inhibition in cancer therapy (19%),
Angiogenesis and VEGF in Cancer (17%),
Glioma Diagnosis and Treatment (11%),
Ovarian cancer diagnosis and treatment (10%)
Wikidata ID:
wiki/Q5057052
OpenAlex ID:
keywords/cediranib
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
2013
·
Rakesh K. Jain
·
Journal of Clinical Oncology
·
1,368
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
2013
·
Tracy T. Batchelor
, Paul Mulholland
, et al.
·
Journal of Clinical Oncology
·
653
PDF
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
2014
·
Joyce F Liu
, William T Barry
, et al.
·
The Lancet Oncology
·
622
A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
2009
·
A. Gregory Sorensen
, Tracy T. Batchelor
, et al.
·
Cancer Research
·
414
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
2013
·
Tracy T. Batchelor
, Elizabeth R. Gerstner
, et al.
·
Proceedings of the National Academy of Sciences
·
367
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages
2016
·
Teresa E. Peterson
, Nathaniel D. Kirkpatrick
, et al.
·
Proceedings of the National Academy of Sciences
·
339
PDF
Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice
2009
·
Walid S. Kamoun
, Carsten D. Ley
, et al.
·
Journal of Clinical Oncology
·
319
Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion
2011
·
A. Gregory Sorensen
, Kyrre E. Emblem
, et al.
·
Cancer Research
·
318
Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
2009
·
Ursula A. Matulonis
, Suzanne Berlin
, et al.
·
Journal of Clinical Oncology
·
317
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
2015
·
Juan W Valle
, Harpreet Wasan
, et al.
·
The Lancet Oncology
·
292
PDF
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
2016
·
Jonathan A Ledermann
, Andrew C Embleton
, et al.
·
The Lancet
·
262
PDF
Novel anti-angiogenic therapies for malignant gliomas
2008
·
Andrew D Norden
, Jan Drappatz
, et al.
·
The Lancet Neurology
·
262
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
2017
·
Jung-Min Lee
, Ashley Cimino-Mathews
, et al.
·
Journal of Clinical Oncology
·
255
Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
2009
·
Glenwood D. Goss
, Andrew Arnold
, et al.
·
Journal of Clinical Oncology
·
237
Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
2012
·
Hans-Joachim Schmoll
, David Cunningham
, et al.
·
Journal of Clinical Oncology
·
229
Cediranib for Metastatic Alveolar Soft Part Sarcoma
2013
·
Shivaani Kummar
, Deborah Allen
, et al.
·
Journal of Clinical Oncology
·
225
Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of “Rebound” Revascularization as Mode of Escape
2011
·
Emmanuelle di Tomaso
, Matija Snuderl
, et al.
·
Cancer Research
·
209
PDF
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
2019
·
J.F. Liu
, W.T. Barry
, et al.
·
Annals of Oncology
·
197
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
2013
·
Joyce F. Liu
, Sara M. Tolaney
, et al.
·
European Journal of Cancer
·
181
Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
2019
·
Alanna R. Kaplan
, Susan E. Gueble
, et al.
·
Science Translational Medicine
·
168
Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
2012
·
Paulo M. Hoff
, Andreas Hochhaus
, et al.
·
Journal of Clinical Oncology
·
166
Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects
2014
·
Tracy T. Batchelor
, David A. Reardon
, et al.
·
Clinical Cancer Research
·
165
Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review
2018
·
Luca Paoluzzi
, Robert G. Maki
·
JAMA Oncology
·
159
Overview of anti-angiogenic agents in development for ovarian cancer
2011
·
Robert A. Burger
·
Gynecologic Oncology
·
150
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
2008
·
Andrew D. Norden
, Jan Drappatz
, et al.
·
Journal of Neuro-Oncology
·
144
Show more works
View as search
Works count:
1,003
Citation count:
20,420
Year
Topic
Type